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compliance-sensitive. CONCLUSIONS: Adhering to GOLD guidelines, apart from 
having patients treated appropriately, National/Regional Healthcare Systems could 
save signiﬁ cant resources and re-allocate them in more rational manner.
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EFFECTIVENESS AND EFFICIENCY OF ME-TOO LISTS AS ILLUSTRATED 
BY THE EXAMPLE OF INTRANASAL STEROIDS
Schoeffski O1, Becker B2
1University Erlangen-Nuernberg, Nuernberg, Germany; 2Essex Pharma, Munich, Germany
OBJECTIVES: A me-too list has been implemented in a German KV (regional associa-
tion of SHI-accredited physicians) with the intention of promoting cost-effective 
prescribing behavior. The aim was to investigate whether the me-too list is an effective 
steering tool. a mometasone-containing nasal spray (MHN) which has been listed as 
a me-too, should be substituted by budesonide-containing nasal sprays (BHN), 
because MHN therapy is assumed to be equally effective but more cost intensive than 
BHN. MHN’s market share has declined after listing. METHODS: A retrospective 
study of anonymized patient data was conducted from March to April 2009 in KV 
North Rhine. ENT physicians documented patients which had received MHN for 
minimum 12 months and who had then been switched to another intranasal steroid 
(INS). Evaluation was done with descriptive statistics. RESULTS: A total of 676 
patients documented by 76 physicians were eligible for the analysis. a total of 189 
patients (28%) received MHN only; a switch to other INS was documented for 487 
patients (72%). ENTs cited economic reasons for changing the INS in 86.4% of the 
cases. Compared to other INS, the average number of consultations for MHN treat-
ment and the administered dose of MHN, regardless of diagnosis, were lower, MHN 
patients required reﬁ ll prescriptions later, less co medication, and MHN generated 
lower daily treatment costs in real-life. CONCLUSIONS: Reasons for switching from 
MHN were economically. Therefore the me-too list has a heavy impact on prescription 
behavior. Daily treatment costs of MHN were lower in real-life. Analysis based on 
PDD (prescribed daily doses) showed that the economic effect of switching a patient 
to another INS was far less than expected. For instance it was offset by a higher 
number of consultations in association with the cheaper alternatives in more frequent 
use. An economic evaluation with a precise quantiﬁ cation would be of major interest 
in future.
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OBJECTIVES: To assess predictive factors and risk proﬁ les for treatment response in 
patients with allergic rhinitis. It was the aim to create a platform giving support to 
the development of interventions optimizing the daily use as well as the sustainability 
of the existing national and international guidelines and therewith minimizing the 
progression to severe chronic upper airway diseases. METHODS: For this purpose, 
76,981 case reports of patients with allergic rhinitis from ten post-marketing-studies 
in Germany were aggregated by the use of an IPD meta-analysis. The data pool was 
examined in terms of signiﬁ cant predictive factors by univariat methods, logistic 
regression and discriminant analysis. The predictive ability of the model was assessed 
by a 10 fold crossvalidation. RESULTS: First, we investigated the data pool as a 
whole, and the results showed that 20.6% of the patients did not respond to their 
therapy. Especially patients who were treated according to current guidelines had a 
higher risk of non-response (28% vs. 19.3%). Next, we examined the data pool in 
terms of signiﬁ cant predictive factors resulting in non-response of patients receiving 
an adequate guideline-conform therapy. The primary baseline determinants were a 
positive history of allergy in the family, duration and severity of disease, the periodicity 
of an allergen (perennial allergens) and concomitant diseases. Especially patients with 
asthma as well as patients suffering from more than one concomitant disease had a 
higher risk of non-response (32.4% and 34%). The main follow up determinants were 
patient’s compliance, safety and the treatment process. a total of 63.4% of patients 
with a poor compliance, which was enforced by an inadequate safety were non-
responder. CONCLUSIONS: These results support the ﬁ ndings of current clinical 
trials describing a non-responder rate of about 20% and encourage efforts to optimize 
guidelines as well as to achieve a sustainability of guidelines. 
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OBJECTIVES: When comparing interventions through routine database research, it 
is important to adjust for COPD severity. GOLD guidelines grade COPD severity 
according to lung function (FEV1% predicted). Most databases lack data on lung 
function. Previous database research has approximated COPD severity using demo-
graphics and health care utilization. This study aims to derive an algorithm for COPD 
severity using baseline data from a large, respiratory trial (UPLIFT). METHODS: 
Several partial proportional odds logit models were used to estimate the probabilities 
of being in GOLD stages II, III and IV. The predicted GOLD stage for each patient 
was deﬁ ned as the state with the highest predicted probability. The concordance 
between the predicted and the observed (according to lung function) stage was assessed 
with κ-statistics. Models were estimated in a random selection of 2/3 of all patients 
enrolled in Western Europe (n = 2439) and validated in the remaining patients (n = 
1259). The ﬁ nal model was re-estimated in a subsample with a balanced distribution 
across severity stages. RESULTS: In the validation set, 47% were in stage II, 44% in 
III, and 9% in IV. In the ﬁ nal model, a higher risk of more severe COPD was associ-
ated with being male, younger, lower BMI, and certain medications (long-acting and 
short-acting bronchodilators, leukotriene modiﬁ ers, oral steroids), oxygen and having 
quit smoking. No relationship was found between severity and co-morbidities, previ-
ous health care resource use (e.g. emergency room, hospitalizations) and inhaled 
corticosteroids, xanthines, or mucolytics. The concordance between observed and 
predicted disease states was generally poor (κ = 0.15) and only slightly better in the 
balanced sample (κ = 0.22). CONCLUSIONS: Data from a well controlled trial setting 
indicated that COPD severity cannot be reliably predicted from demographics and 
health care use. This limitation should be considered when interpreting ﬁ ndings from 
database studies, and additional research should explore other methods allowing to 
account for COPD severity.
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OBJECTIVES: Propensity score matching and standard regression analysis are 
common ways to control for baseline differences between comparative groups. They 
control for observable factors. Instrumental variable approach controls not only for 
observable factors but also unobservable factors. We compared the three methods and 
showed that using more advanced techniques alters the estimated results in a signiﬁ -
cant way. METHODS: Using data from U.S. claims databases, the effect of treatment 
on total health care expenditures among asthma patients was estimated. Reimburse-
ment amounts were dollars paid by the health plan to the provider including patient 
co-payments and deductibles. Doctors’ prescribing patterns were used as an instru-
mental variable for treatment choice. Propensity score matching was employed using 
the nearest neighbor matching algorithm. Generalized linear model was used as an 
alternative risk adjustment technique. RESULTS: Patients treated with control medica-
tion were younger, more likely to live in the northeast and south of the United States 
and have a higher Charlson comorbidity score, Elixhauser score and chronic disease 
score relative to patients treated with reliever medication. The difference between one 
year health care costs for reliever and controller medication was $2,345 by propensity 
score matching, $2,195 by generalized linear model, and $2,997 by instrumental 
variable approach. The difference was statistically signiﬁ cant. CONCLUSIONS: After 
adjusting for patient clinical and demographic characteristics, controller medication 
was less costly than reliever medication. The choice of risk adjustment was important. 
The technique that controlled for both observed and unobserved biases (instrumental 
variable technique) provided a difference of almost 30% higher than the other 
techniques.
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OBJECTIVES: Estimation of cost differences between groups has been assessed using 
a variety of econometric techniques. Recent literature commonly uses ordinary least 
squares (OLS) with log transformed costs or generalized linear models with a log link 
function and gamma error distribution; however recommendations from the ﬁ eld of 
econometrics suggest that quantile regression models may provide more informative 
comparisons of health care cost data. The objective of this study was to compare three 
econometric models for estimating health care cost differences. METHODS: The 
econometric models were compared using a cross-sectional sample of patients hospital-
ized during 2007 for COPD exacerbations from Premier’s Perspective Comparative 
Database, a population-based U.S. inpatient database. Admissions were classiﬁ ed into 
two groups according to the presence of pneumonia. Total inpatient cost was regressed 
on pneumonia status and confounders using: 1) OLS with log-transformed costs; 2) 
generalized linear models with log link and gamma error; and 3) quantile regression 
with comparisons at every 5th percentile. Cost differences were calculated by subtract-
ing model based estimated costs between COPD patients with and without pneumo-
nia. RESULTS: There were 69,841 COPD exacerbation admissions. Of these, 69,286 
admissions had nonzero costs, and 6,840 (9.9%) had evidence of pneumonia. In the 
OLS model, estimated costs were $3,949 (95%CI: $3,822–$4,076) higher in patients 
with pneumonia; in the log-gamma model, the estimated costs were $4,442 (95%CI: 
